Ivermectin and Cancer: Evidence and Ongoing Research

Ivermectin and Cancer: Evidence and Ongoing Research- If conventional cancer therapies worked 100% of the time, without debilitating side effects, there would be no need to study repurposed drugs like ivermectin. Sadly, this is not the case.

But that is not to say that repurposed drugs like ivermectin are without serious risks.

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.

The post below is PeopleBeatingCancer’s effort to weigh in on the ivermectin and cancer debate. Please scroll down the page, post a question or a comment if you have any questions.

If you’d like to learn more about repurposed drugs and cancer treatment, click now.

Thank you,

David Emerson

Ivermectin to Treat Cancer? Get the FACTS

Introduction

Ivermectin is a medication widely used to treat parasitic infections in humans and animals. Since its introduction in the late 20th century, it has become one of the most successful antiparasitic drugs ever developed and has played a major role in global public health campaigns targeting diseases such as river blindness and lymphatic filariasis.

In recent years, ivermectin has attracted growing attention from cancer researchers. Laboratory studies have suggested that ivermectin may influence several biological pathways involved in tumor growth, including cell proliferation, apoptosis (programmed cell death), and immune signaling. Because of these effects, scientists have begun exploring whether ivermectin might have potential as an adjunct or complementary therapy in oncology.

Although interest in ivermectin and cancer has increased, the majority of research remains in early experimental stages. This article reviews what current studies show—including laboratory research, animal experiments, and early clinical investigations—to clarify what scientists currently understand about ivermectin’s potential role in cancer therapy.

What Is Ivermectin?

Ivermectin is a member of a class of drugs known as macrocyclic lactones. It was first developed in the 1970s and has since been widely used to treat parasitic infections such as strongyloidiasis, onchocerciasis, and scabies.

The drug works primarily by binding to specific ion channels in parasites, disrupting nerve and muscle function and leading to paralysis and death of the parasite. In humans, ivermectin is generally well tolerated when used at approved doses for parasitic infections.

Beyond its antiparasitic activity, ivermectin has been found to interact with multiple cellular signaling pathways. Some of these pathways are involved in cancer development and progression, which has led researchers to investigate its potential anticancer properties.

Why Researchers Study Ivermectin for Cancer

Laboratory studies suggest ivermectin may affect several biological processes relevant to cancer development.

Proposed mechanisms include:

• Induction of apoptosis – triggering programmed cancer cell death
• Inhibition of tumor cell proliferation – slowing or stopping cell division
• Modulation of signaling pathways – including WNT/β-catenin and PI3K/Akt pathways
• Disruption of mitochondrial function – affecting tumor cell metabolism
• Immune system modulation – potentially enhancing anti-tumor immune responses

Because many cancers rely on abnormal activation of these pathways, drugs that interfere with them can sometimes inhibit tumor growth.

Cancer Types Studied

Research investigating ivermectin’s anticancer potential has examined a variety of tumor types.

Ivermectin and Breast Cancer Research

Several laboratory studies have reported that ivermectin may suppress proliferation of breast cancer cells and induce apoptosis. Some research suggests ivermectin may influence signaling pathways involved in breast tumor growth.

Ivermectin and Colorectal Cancer Research

Studies in colorectal cancer cell lines have suggested that ivermectin may inhibit tumor cell proliferation and promote programmed cell death through effects on cellular signaling pathways.

Ivermectin and Lung Cancer Research

Research involving lung cancer models has explored ivermectin’s ability to interfere with cancer cell growth and tumor metabolism. Some studies suggest potential synergy with chemotherapy agents.

Ivermectin and Leukemia Research

Certain laboratory experiments have indicated that ivermectin may induce apoptosis in leukemia cells and interfere with cancer cell survival pathways.

Ivermectin and Brain Cancer Research

Early research has also examined ivermectin’s effects on glioblastoma cells, suggesting possible anti-tumor mechanisms through disruption of signaling pathways and cellular metabolism.

Laboratory Research

A growing number of laboratory studies have examined ivermectin’s potential anticancer effects in cancer cell lines.

Researchers have observed that ivermectin can inhibit the proliferation of tumor cells across several cancer types. In some studies, ivermectin appears to trigger apoptosis and interfere with cellular pathways that tumors use to grow and spread.

One pathway frequently studied is the WNT/β-catenin signaling pathway, which plays a role in many cancers. Some laboratory findings suggest ivermectin may suppress this pathway, potentially reducing tumor growth.

Additionally, ivermectin has been reported to disrupt mitochondrial function in certain cancer cells, which may impair their ability to produce energy and survive.

Animal Studies

Animal experiments provide another level of evidence in evaluating potential anticancer therapies.

In some mouse tumor models, ivermectin has demonstrated the ability to slow tumor growth. These studies suggest that ivermectin’s effects on signaling pathways and cancer metabolism may contribute to anti-tumor activity in vivo.

However, as with many experimental treatments, results from animal studies do not always translate into effective therapies in humans. Further research is required to determine whether these findings have clinical significance.

Human Clinical Evidence

At present, human clinical trials specifically evaluating ivermectin as a cancer treatment are limited.

Most of the existing evidence comes from:

• laboratory experiments
• animal studies
• exploratory research

Some early clinical studies have explored ivermectin in combination with other therapies, but large randomized controlled trials are currently lacking.

Without such trials, it is not yet possible to determine whether ivermectin is effective or safe as a cancer treatment in humans.

Potential Benefits Suggested by Research

Based on preclinical studies, researchers have proposed several possible anticancer effects of ivermectin:

• inhibition of tumor cell growth
• induction of apoptosis
• suppression of oncogenic signaling pathways
• interference with cancer cell metabolism
• possible synergy with certain anticancer therapies

These findings are promising but remain preliminary.

Limitations and Concerns

Several important limitations should be considered when evaluating ivermectin for cancer.

First, most research remains preclinical, meaning it has been conducted in cell cultures or animal models rather than human patients.
Second, doses used in laboratory experiments may differ from those approved for human use.
Third, interactions between ivermectin and chemotherapy, radiation therapy, or other cancer treatments have not been fully studied.

For these reasons, ivermectin cannot currently be considered an established cancer therapy.

Practical Considerations for Patients

Patients interested in complementary or integrative approaches to cancer care should discuss any therapy with their oncology team.

Important considerations include:

• possible drug interactions
• safety and toxicity
• individual treatment plans
• underlying health conditions

Integrative oncology aims to combine evidence-based complementary therapies with conventional cancer treatment in ways that support patient safety and outcomes.

Related Integrative Therapies Being Studied

Researchers are also investigating several other complementary therapies in cancer care, including:

• Curcumin and cancer
• Melatonin and cancer
• Medicinal mushrooms and cancer
• Omega-3 fatty acids and cancer
• Exercise and cancer survival

Some of these therapies have been examined in human clinical trials and are increasingly studied within integrative oncology programs.

Key Takeaways

• Ivermectin is a well-known antiparasitic drug that has attracted interest in cancer research.
• Laboratory studies suggest it may influence tumor cell signaling pathways and metabolism.
• Animal experiments have shown possible tumor-suppressing effects in some models.
• Human clinical trials evaluating ivermectin for cancer remain limited.
• More research is needed to determine whether ivermectin has a safe or effective role in cancer treatment.

Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!